Other proposed biomarkers in fibromyalgia, such as serum brain-derived neurotrophic factor (BDNF) levels or cerebrospinal fluid cytokine profiles, may offer greater pathophysiological specificity but require specialized assays or invasive procedures, making them impractical for routine clinical use. This evidence concerns the gene BDNF and fibromyalgia.